NICE Gives Nucala Initial OK In Severe Asthma After GSK Offers Price Cut
Adult patients with severe eosinophilic asthma in England and Wales look set to get a much needed treatment option following NICE's provisional backing of GlaxoSmithKline's new MAb therapy.
You may also be interested in...
An 'imperfect biomarker' – that's how a New England Journal of Medicine editorial describes the eosinophil count used in METREX and METREO studies.
GlaxoSmithKline is cementing its leadership position in eosinophilic conditions with promising pivotal results with Nucala as an add-on therapy for the rare disorder eosinophilic granulomatosis with polyangiitis. The development is expected to lead to an extension of its indications.
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.